Hospital
Riverside Healthcare System, L.P.
Riverside Healthcare System, L.P. was paid $65.58M by Medicaid between Jan 2018 and Nov 2024, across 296 billing codes. Its largest line is 99283, emergency room visit (moderate) — 43% of everything it billed.
33Billing provider infoRIVERSIDE HEALTHCARE SYSTEM, L.P.
RIVERSIDE, CA 92501
RIVERSIDE, CA 92501
33aNPI1154368116assigned 05/31/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$65.58M
24GClaims1,713,986
24DCodes billed296
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#43 of 410
Median peer was paid$6.90M
This provider vs. median9.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 263,160 | $11.80M | |
| 2019 | 277,184 | $10.93M | |
| 2020 | 198,695 | $7.12M | |
| 2021 | 211,685 | $7.77M | |
| 2022 | 227,922 | $9.09M | |
| 2023 | 280,718 | $9.94M | |
| 2024incomplete | 254,622 | $8.93M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 43% | 118,361 | 106,347 | $27.91M |
| 0450 | Emergency room services | 41% | 116,022 | 101,185 | $26.58M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 3.0% | 10,313 | 9,550 | $1.96M |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 2.3% | 6,221 | 5,276 | $1.49M |
| 0360 | 1.1% | 6,327 | 3,334 | $726K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,482 | 2,428 | $584K |
| Z7502 | <1% | 15,153 | 15,015 | $565K | |
| 99070 | <1% | 91,945 | 53,840 | $509K | |
| 93458 | <1% | 515 | 487 | $460K | |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 1,706 | 1,486 | $406K |
| 0272 | <1% | 6,179 | 5,838 | $395K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,295 | 1,244 | $311K |
284 more codes
| 99221 | <1% | 2,041 | $302K | |
| 0710 | <1% | 3,975 | $296K | |
| G0384 | Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 1,017 | $245K |
| 99285 | Emergency room visit (most serious) | <1% | 1,603 | $215K |
| 0370 | <1% | 122 | $209K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,334 | $186K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,088 | $175K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 6,047 | $151K |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 547 | $131K |
| J3490 | Unclassified drugs | <1% | 14,734 | $103K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 1,494 | $81K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,794 | $77K |
| 99218 | <1% | 509 | $77K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 2,100 | $72K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 32,702 | $68K |
| 99152 | <1% | 1,223 | $61K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 1,013 | $56K |
| 77336 | <1% | 82 | $51K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 17,620 | $49K |
| 88312 | <1% | 2,353 | $47K | |
| 80053 | Comprehensive metabolic panel | <1% | 103,426 | $40K |
| 88307 | <1% | 854 | $39K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,351 | $38K |
| 85027 | <1% | 125,399 | $33K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 57,803 | $31K |
| 93798 | <1% | 1,347 | $30K | |
| 0762 | <1% | 1,506 | $26K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 33,167 | $26K |
| 99217 | <1% | 522 | $24K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 822 | $23K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 19,439 | $23K |
| 71045 | Radiologic examination, chest; single view | <1% | 48,435 | $22K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 14,773 | $21K |
| 99224 | <1% | 358 | $20K | |
| 0250 | <1% | 68,538 | $20K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 627 | $20K |
| 82803 | <1% | 2,053 | $19K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 343 | $18K |
| 88304 | <1% | 1,575 | $18K | |
| 76642 | <1% | 274 | $17K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,563 | $17K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 22,195 | $16K |
| G0378 | Hospital observation service, per hour | <1% | 2,589 | $15K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,796 | $15K |
| 47562 | <1% | 60 | $15K | |
| 76937 | <1% | 731 | $14K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 543 | $13K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,472 | $13K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 267 | $13K |
| 99225 | <1% | 222 | $13K | |
| 58558 | <1% | 119 | $12K | |
| G0380 | Level 1 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 42 | $10K |
| 77300 | <1% | 15 | $10K | |
| 0270 | <1% | 1,921 | $10K | |
| 73610 | <1% | 5,157 | $9K | |
| Z7610 | <1% | 883 | $9K | |
| 77334 | <1% | 17 | $9K | |
| 73630 | <1% | 5,572 | $8K | |
| 75572 | <1% | 39 | $8K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 170 | $8K |
| 86923 | <1% | 82 | $8K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,101 | $8K |
| 88341 | <1% | 76 | $7K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 13,141 | $7K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 16,719 | $7K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,148 | $7K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 11,682 | $7K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,028 | $6K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 174 | $6K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 7,900 | $6K |
| 93970 | <1% | 471 | $6K | |
| 73562 | <1% | 5,446 | $5K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 133 | $5K |
| 86920 | <1% | 48 | $5K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 30,351 | $5K |
| 73502 | <1% | 1,689 | $5K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,939 | $4K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 124 | $4K |
| 85610 | <1% | 16,194 | $4K | |
| 93971 | <1% | 3,166 | $4K | |
| 83690 | <1% | 70,221 | $4K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 3,261 | $4K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,941 | $4K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 6,998 | $4K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 43 | $4K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,024 | $4K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 7,907 | $4K |
| 86850 | <1% | 8,015 | $4K | |
| 77066 | Tomosynthesis, mammo | <1% | 25 | $4K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 7,676 | $4K |
| 73590 | <1% | 2,198 | $4K | |
| 91035 | <1% | 24 | $4K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,329 | $3K |
| 88342 | <1% | 230 | $3K | |
| 58661 | <1% | 15 | $3K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 586 | $3K |
| 73552 | <1% | 450 | $3K | |
| 87070 | <1% | 827 | $3K | |
| 73110 | <1% | 3,272 | $3K | |
| 86901 | <1% | 13,685 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 5,405 | $3K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 43 | $3K |
| 85730 | <1% | 11,830 | $3K | |
| 86900 | <1% | 13,677 | $3K | |
| 71250 | <1% | 72 | $3K | |
| 77065 | Tomosynthesis, mammo | <1% | 25 | $3K |
| 87077 | <1% | 551 | $3K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 490 | $3K |
| 88313 | <1% | 121 | $3K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,243 | $3K |
| 76641 | <1% | 21 | $3K | |
| 73030 | <1% | 3,491 | $2K | |
| 84484 | <1% | 48,259 | $2K | |
| 0682 | <1% | 320 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,939 | $2K |
| 73080 | <1% | 2,372 | $2K | |
| 80061 | Lipid panel | <1% | 2,621 | $2K |
| 73130 | <1% | 4,255 | $2K | |
| 83735 | <1% | 6,880 | $2K | |
| 83880 | <1% | 9,989 | $2K | |
| 96376 | <1% | 1,581 | $2K | |
| 87186 | <1% | 2,648 | $2K | |
| 72100 | <1% | 2,195 | $2K | |
| 0510 | <1% | 49 | $2K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 61 | $2K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,914 | $1K |
| A9505 | Thallium tl-201 thallous chloride, diagnostic, per millicurie | <1% | 32 | $1K |
| 84703 | <1% | 42,041 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,441 | $1K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 247 | $1K |
| 70496 | <1% | 521 | $1K | |
| 73090 | <1% | 1,857 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,131 | $1K |
| 74018 | <1% | 1,361 | $1K | |
| 84100 | <1% | 4,590 | $1K | |
| 76770 | <1% | 137 | $1K | |
| 87205 | <1% | 691 | $1K | |
| 70486 | <1% | 1,718 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 41,321 | $1K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 22,802 | $1K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,312 | $1K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 33 | $1K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,658 | $1K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 43 | $995.16 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 716 | $981.06 |
| 88302 | <1% | 42 | $923.12 | |
| 72040 | <1% | 1,022 | $906.50 | |
| 83605 | <1% | 6,577 | $842.04 | |
| 81001 | <1% | 32,944 | $832.39 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 102 | $826.59 |
| 80074 | <1% | 340 | $786.94 | |
| 72131 | <1% | 375 | $733.62 | |
| 70498 | <1% | 609 | $713.12 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 13 | $701.45 |
| 87040 | <1% | 6,683 | $647.75 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,806 | $641.06 |
| 74174 | <1% | 12 | $627.02 | |
| 12002 | <1% | 833 | $585.16 | |
| 76801 | <1% | 2,933 | $575.76 | |
| 73060 | <1% | 351 | $574.70 | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 14 | $553.98 |
| 12001 | <1% | 1,669 | $506.44 | |
| 93017 | <1% | 89 | $483.68 | |
| 82140 | <1% | 1,155 | $483.24 | |
| 10060 | <1% | 1,070 | $479.44 | |
| 73560 | <1% | 47 | $464.21 | |
| J7070 | Infusion, d5w, 1000 cc | <1% | 49 | $463.74 |
| 87486 | <1% | 258 | $440.63 | |
| 80197 | <1% | 97 | $438.96 | |
| 84439 | <1% | 2,365 | $438.19 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 79 | $433.73 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 720 | $421.23 |
| 29515 | <1% | 414 | $413.47 | |
| 82553 | <1% | 312 | $405.85 | |
| 82150 | <1% | 3,968 | $377.48 | |
| 0258 | <1% | 510 | $373.71 | |
| 84702 | <1% | 8,176 | $370.54 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,057 | $368.40 |
| 85384 | <1% | 1,260 | $367.71 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,202 | $327.78 |
| 72170 | <1% | 237 | $319.15 | |
| 76870 | <1% | 706 | $313.98 | |
| 82550 | <1% | 1,895 | $304.04 | |
| 88300 | <1% | 114 | $277.15 | |
| 73140 | <1% | 1,261 | $275.66 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,669 | $273.68 |
| 70491 | <1% | 73 | $269.51 | |
| 72050 | <1% | 209 | $252.30 | |
| 86140 | <1% | 3,393 | $233.97 | |
| 87581 | <1% | 250 | $223.14 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 247 | $223.14 |
| 82570 | <1% | 1,118 | $218.24 | |
| 29125 | <1% | 1,238 | $218.01 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 190 | $213.10 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 9,160 | $212.57 |
| 90715 | <1% | 1,879 | $187.03 | |
| 87631 | <1% | 2,256 | $177.10 | |
| 87497 | <1% | 22 | $171.02 | |
| 84156 | <1% | 1,270 | $166.49 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 872 | $163.16 |
| 59025 | Fetal non-stress test | <1% | 167 | $152.42 |
| 96367 | <1% | 247 | $150.22 | |
| J2704 | Injection, propofol, 10 mg | <1% | 66 | $132.05 |
| 12011 | <1% | 1,228 | $131.99 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,023 | $129.47 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,102 | $117.14 |
| 85652 | <1% | 2,806 | $113.05 | |
| 87088 | <1% | 2,477 | $110.61 | |
| 84550 | <1% | 1,441 | $102.82 | |
| 82728 | <1% | 661 | $98.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,023 | $93.21 |
| 82607 | <1% | 179 | $92.76 | |
| 82746 | <1% | 123 | $92.22 | |
| 80076 | <1% | 927 | $90.65 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,234 | $90.51 |
| 94664 | <1% | 171 | $89.82 | |
| 85379 | <1% | 2,483 | $84.96 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 33 | $84.00 |
| 84145 | <1% | 51 | $77.28 | |
| 84134 | <1% | 50 | $72.35 | |
| 83615 | <1% | 866 | $70.58 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 21 | $65.05 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,366 | $63.98 |
| 74019 | <1% | 217 | $58.50 | |
| 0259 | <1% | 135 | $51.12 | |
| 83550 | <1% | 140 | $47.94 | |
| 83540 | <1% | 158 | $39.84 | |
| 86780 | <1% | 220 | $39.67 | |
| 81003 | <1% | 970 | $38.26 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 374 | $35.28 |
| 90714 | <1% | 953 | $32.47 | |
| 87210 | <1% | 2,436 | $30.92 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,259 | $21.46 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 126 | $21.15 |
| 82248 | <1% | 42 | $20.48 | |
| 87800 | <1% | 590 | $19.39 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 57 | $17.50 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,178 | $17.39 |
| 82565 | <1% | 216 | $15.99 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 142 | $14.25 |
| A9270 | Non-covered item or service | <1% | 4,890 | $10.54 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,679 | $10.00 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,681 | $10.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 902 | $6.45 |
| 82330 | <1% | 12 | $4.95 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 163 | $3.40 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 401 | $0.99 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 91 | $0.48 |
| 96368 | 0% | 71 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 127 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 49 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 412 | $0.00 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 0% | 27 | $0.00 |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 0% | 123 | $0.00 |
| 73660 | 0% | 14 | $0.00 | |
| C1769 | Guide wire | 0% | 62 | $0.00 |
| 72128 | 0% | 13 | $0.00 | |
| 12013 | 0% | 12 | $0.00 | |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | 0% | 29 | $0.00 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 15 | $0.00 |
| 76604 | 0% | 41 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 31 | $0.00 |
| 86592 | 0% | 13 | $0.00 | |
| 84132 | 0% | 12 | $0.00 | |
| 87483 | 0% | 17 | $0.00 | |
| 82010 | 0% | 665 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 303 | $0.00 |
| 72070 | 0% | 744 | $0.00 | |
| 0681 | 0% | 1,245 | $0.00 | |
| 76376 | 0% | 160 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 49 | $0.00 |
| 0637 | 0% | 191 | $0.00 | |
| Q0114 | Fern test | 0% | 348 | $0.00 |
| 80164 | 0% | 79 | $0.00 | |
| 70360 | 0% | 43 | $0.00 | |
| 29105 | 0% | 14 | $0.00 | |
| 71010 | 0% | 20 | $0.00 | |
| 87150 | 0% | 12 | $0.00 | |
| 69200 | 0% | 12 | $0.00 | |
| 51702 | 0% | 37 | $0.00 | |
| 93308 | 0% | 12 | $0.00 | |
| 72110 | 0% | 25 | $0.00 | |
| 84295 | 0% | 12 | $0.00 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLACAZE, ASHLEY (CFO)
| Provider | Location | Paid |
|---|---|---|
| Riverside Healthcare System, L.P. | Riverside, CA | $4.92M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.